Business Context and Reporting Period
This Form 6-K filing by Alcon, Inc. is dated April 24, 2003. The report details a revision to the company's sales presentation methodology for 2003. Alcon shifted from reporting sales by specific products to reporting by therapeutic category to better reflect internal business reviews. The filing provides restated comparative data for 2002 and 2001 to align with this new format.
Key Financial Metrics
The filing provides restated sales data (in millions) for the full years 2002 and 2001, broken down by segment:
| Segment | 2002 Full Year | 2001 Full Year |
|---|---|---|
| Total Pharmaceuticals | $1,090.2 | $927.7 |
| Total Surgical | $1,438.5 | $1,357.7 |
| Total Consumer | $480.4 | $462.3 |
| Total Sales | $3,009.1 | $2,747.7 |
The filing does not provide data regarding profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the reclassification of sales categories. Significant reclassifications include:
- Sales of steroids moved from "Other Pharmaceuticals" to "Infection/Inflammation Products."
- Refractive service sales moved from "Other Surgical" to "Refractive Products."
- Viscoelastics and the remainder of "Other Surgical" moved to "Cat/Vit Products."
Under the revised format, Total Sales for 2002 are reported as $3,009.1 million compared to $2,747.7 million in 2001.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, specific risk factors, contingencies, or unusual items beyond the accounting presentation change.
Investor Verification Checklist
- Verify the impact of the reclassification on year-over-year growth rates for specific therapeutic categories.
- Confirm that the 2002 and 2001 figures presented are fully restated to match the 2003 reporting format.
- Note that this filing contains only sales data; verify profit and cash flow metrics in other filings (e.g., Form 20-F).